Published online March 1, 2005
PEDIATRICS Vol. 115 No. 3 March 2005, pp. 827-828 (doi:10.1542/peds.2004-2425)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Best, E. J.
Right arrow Articles by Gazarian, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Best, E. J.
Right arrow Articles by Gazarian, M.
Related Collections
Right arrow Infectious Disease & Immunity

Extended-Interval Aminoglycosides in Children: More Guidance Is Needed

E. J. Best, MBChB
P. Palasanthiran, MD, FRACP
School of Women's and Children's Health,
University of New South Wales,
New South Wales 2031, Australia,
Immunology and Infectious Diseases,
Sydney Children's Hospital,
New South Wales 2031, Australia

M. Gazarian, MBBS, MSc(ClinEpi), FRACP
School of Women's and Children's Health,
University of New South Wales,
New South Wales 2031, Australia,
Clinical Pharmacology and Therapeutics,
Sydney Children's Hospital,
New South Wales 2031, Australia

The first 20% of the full text of this article appears below.

To the Editor.—

We read with interest the article by Contopoulos-Ioannidis et al in the July 2004 issue of Pediatrics.1 We welcome this collation of pediatric data on the efficacy and safety of extended-interval aminoglycoside dosing (EIAD), given the lack . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
R Cristobal and J S Oghalai
Hearing loss in children with very low birth weight: current review of epidemiology and pathophysiology
Arch. Dis. Child. Fetal Neonatal Ed., November 1, 2008; 93(6): F462 - F468.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
J. E. Murphy and A. M. Roether
Two nomograms for determining extended-dosing intervals for gentamicin in neonates
Am. J. Health Syst. Pharm., April 1, 2008; 65(7): 624 - 630.
[Abstract] [Full Text] [PDF]